Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy

Recent discoveries in the disease pathophysiology of pulmonary arterial hypertension have been translated into effective therapies tested in clinical trials. The studies have focused on surrogate and intermediate end points, thought to reflect quantity and quality of life, respectively. The authors...

Full description

Saved in:
Bibliographic Details
Published inClinics in chest medicine Vol. 28; no. 1; p. 75
Main Authors Snow, Jennifer L, Kawut, Steven M
Format Journal Article
LanguageEnglish
Published United States 01.03.2007
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Recent discoveries in the disease pathophysiology of pulmonary arterial hypertension have been translated into effective therapies tested in clinical trials. The studies have focused on surrogate and intermediate end points, thought to reflect quantity and quality of life, respectively. The authors present the necessary requirements for establishing the reliability and validity of such end points before they may be used dependably. The authors also review the available data, strengths, and weaknesses of potential end points in pulmonary arterial hypertension.
ISSN:0272-5231
DOI:10.1016/j.ccm.2006.11.005